New Launch1 Dec 2025, 09:14 am
Sun Pharma Launches Global Innovative Drug Ilumya in India for Moderate-to-Severe Plaque Psoriasis
AI Summary
Sun Pharmaceutical Industries Ltd. has launched its global innovative drug, Ilumya (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis. Ilumya is a novel biologic treatment that has been widely endorsed by dermatologists in the US and worldwide. Sun Pharma's clinical study in India showed significant and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis. Ilumya is the first IL-23 inhibitor to complete five years of study, making it a sustainable choice for patients over the long term.
Key Highlights
- Sun Pharma launches Ilumya, a global innovative drug, in India for moderate-to-severe plaque psoriasis.
- Ilumya is a novel biologic treatment that has been endorsed widely by dermatologists in the US and worldwide.
- Sun Pharma's clinical study in India showed significant and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
- Ilumya is the first IL-23 inhibitor to complete five years of study, making it a sustainable choice for patients over the long term.